ClinicalTrials.gg
RecruitingNCT07226349Updated Sep 28, 2026

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Phase 1 interventional study of BG-75098 and BGB-43395 in Advanced Solid Tumor, sponsored by BeOne Medicines. Recruiting at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Sep 28, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Read the detailed description

This study will be conducted in 2 phases: Phase 1a Dose Escalation and Phase 1b Dose Expansion.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Cyclin-Dependent Kinase 2- Targeted Protein Degrader
  • CDK2
  • CDK4
  • CDK4 inhibitor
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have as assessed by v1.1.
  • Participants must have a stable (ECOG) Performance Status of 0 or 1.
  • Participants must have adequate organ function.
  • Dose Escalation Part A: Participants with or cytologically confirmed advanced, , or unresectable solid tumors potentially associated with cyclin-dependent kinase 2 (CDK2) dependency. Participants should have received prior treatment with available standard-of-care (SOC) systemic therapies for advanced/metastatic disease, or for whom standard therapy is not available or not tolerated.
  • Dose Escalation Part B: Patients with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors who have received ≥ 1 in the metastatic setting.
  • Dose Expansion Cohort 1: Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable CDK4/6 inhibitor-progressed solid tumors.
  • Dose Expansion Cohort 2: Participants with advanced solid tumors. Participants with primary platinum disease are not eligible. Participants should have received ≥ 1 line of platinum-containing chemotherapy and ≤ 4 prior therapeutic regimens in the advanced/metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • For all cohorts: Prior therapy selectively targeting CDK2 inhibition or degradation.
  • For combination cohorts: Prior therapy selectively targeting CDK4. Prior CDK4/6 inhibitor standard of care therapy is permitted and required in local regions where it is approved and available.
  • Participants with active or uncontrolled, untreated .

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Phase 1a, Part A: Dose Escalation, BG-75098 Monotherapy

    Sequential cohorts of increasing dose levels of BG-75098 will be evaluated as monotherapy.

    Drug: BG-75098

  • Experimental
    Phase 1a, Part B: Dose Escalation, BG-75098 Combination

    Sequential cohorts of increasing dose levels of BG-75098 will be evaluated in combination with BGB-43395 and fulvestrant.

    Drug: BG-75098 · Drug: BGB-43395 · Drug: Fulvestrant

  • Experimental
    Phase 1b, Cohort 1: Dose Expansion, BG-75098 Combination

    Participants will receive BG-75098 at the recommended dose level from Phase 1a in combination with BGB-43395 and fulvestrant.

    Drug: BG-75098 · Drug: BGB-43395 · Drug: Fulvestrant

  • Experimental
    Phase 1b, Cohort 2: Dose Expansion, BG-75098 Monotherapy

    Participants will receive BG-75098 as monotherapy at the recommended dose level from Phase 1a.

    Drug: BG-75098

Interventions

  • DrugBG-75098

    Administered orally.

  • Administered orally.

  • Administered by intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants with Adverse Events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including physical examination findings, electrocardiogram results, laboratory values, and AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria.

    Time frame: From first dose to 30 days after last dose, up to approximately 12 months

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-75098

    MTD is determined based on a target for dose-limiting toxicities. MAD is defined as the maximum administered dose, and it is used when MTD is not reached.

    Time frame: Up to approximately 2 years

  3. Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-75098 as Monotherapy and in Combination with BGB-43395 and Fulvestrant

    The RDFE(s) will be determined from safety, tolerability, pharmacokinetic, pharmacodynamic biomarker(s), preliminary antitumor activity, and any other relevant data that are obtained from the dose escalation phase.

    Time frame: Up to approximately 2 years

  4. Phase 1b: Objective Response Rate (ORR) as Assessed by the Investigator

    ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR), as assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Phase 1a: ORR as Assessed by the Investigator

    ORR is defined as the percentage of participants with best overall response of CR or PR, as assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Phase 1a: Duration of Response (DOR) as Assessed by the Investigator

    DOR is defined as the time from the first confirmed objective response assessed by the investigator using RECIST v1.1 until the first documentation of disease progression after treatment initiation or death, whichever comes first.

    Time frame: Up to approximately 2 years

  3. Phase 1a: Time to Response (TTR) as Assessed by the Investigator

    TTR is defined as the time from treatment initiation to the first determination of overall response assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Phase 1a: Progression-Free Survival (PFS) as Assessed by the Investigator

    PFS is defined as the time from the date of the first dose of study treatment to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. Phase 1b: DOR as Assessed by the Investigator

    DOR is defined as the time from the first confirmed objective response assessed by the investigator using RECIST v1.1 until the first documentation of disease progression after treatment initiation or death, whichever comes first.

    Time frame: Up to approximately 2 years

  6. Phase 1b: TTR as Assessed by the Investigator

    TTR is defined as the time from treatment initiation to the first determination of overall response assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 2 years

  7. Phase 1b: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a best overall response, of CR, PR, or stable disease assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 2 years

  8. Phase 1b: Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks.

    Time frame: Up to approximately 2 years

  9. Phase 1b: PFS

    PFS is defined as the time from the date of the first dose of study treatment to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

    Time frame: Up to approximately 2 years

  10. Phase 1b: Number of Participants with AEs

    Number of participants with TEAEs and SAEs, including physical examination findings, electrocardiogram results, and laboratory values.

    Time frame: Up to approximately 2 years

  11. Observed Plasma Maximum Concentration (Cmax) of BG-75098

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  12. Observed Plasma Trough Concentration (Ctrough) of BG-75098

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  13. Area Under the Concentration-Time Curve (AUC) of BG-75098

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  14. Terminal Half-Life (t1/2) of BG-75098

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  15. Phase 1b: Plasma Concentrations of BG-75098

    Time frame: Assessed at select time points between Cycle 1 and Cycle 7 (each Cycle is 28 days)

  16. Phase 1a: Observed Plasma Maximum Concentration (Cmax) of BGB-43395

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  17. Phase 1a: Observed Plasma Trough Concentration (Ctrough) of BGB-43395

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  18. Phase 1a: Area Under the Concentration-Time Curve (AUC) of BGB-43395

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  19. Phase 1a: Terminal Half-Life (t1/2) of BGB-43395

    Time frame: Assessed at select time points between Cycle 1 and Cycle 2 (each Cycle is 28 days)

  20. Plasma Concentrations of BGB-43395

    Time frame: Assessed at select time points between Cycle 1 and Cycle 7 (each Cycle is 28 days)

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • City of Hope National Medical Center · Duarte, United States
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added
    Show site
    • City of Hope National Medical Center · Duarte, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226349
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Dec 11, 2025
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
8778285568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion